Most Exhaustive Report

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2018

SKU : APA17806
  • Published on : February 2018

Get free sample Customize this report

Get 10% Free Customization In This Report. Get In Touch Now

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2018

Advent Tumor Necrosis Factor Alpha (TNF-a) inhibitors represent one a major treatment paradigm for inflammatory diseases. Anti TNF-a drug class one of the most commercially successful drug classes in the pharmaceutical industry worldwide. Currently marketed anti-TNF-a drugs are among the top five global block buster drugs.  Cumulative sales of top three TNF-a inhibitors (Remicade, Enbrel, Humira) surpassed $32 billion in 2016.

TNF-a inhibitors exhibit therapeutic efficacy blocking the activity of tumor necrosis factor (TNF), a cytokine that causes inflammation and leads to diverse immune-system diseases. Apparently, almost all the currently marketed TNF-a drugs are indicated for wide spectrum of immune-related disorders such as – Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and uveitis. Advances in biological research is uncovering further therapeutic benefits of this drug class for wider indications. Currently clinical research is focused on evaluating therapeutic efficacy and safety of TNF-a inhibitors on wide range of other inflammatory diseases, neurodegenerative diseases and multiple cancers.

Reasons to buy

  • To gain erudite insights on TNF-a inhibitor pipeline landscape
  • Ascertain unique product development dynamics and leverage it for novel target identification, drug repositioning and precision medicine.
  • For optimization of pipeline product portfolio in correspondence with ever dynamic pharmaceutical market
  • Identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain well-informed updates on drug termination/drug discontinuations

Our reports have been trusted by the best



Single License
5 User License
Corporate License


Get in touch if you have any queries regarding this report or get insights.



Copyright 2019 - Arizton